An open label randomized controlled trial of atorvastatin versus aspirin in elite controllers and antiretroviral-treated people with HIV
暂无分享,去创建一个
S. Migueles | R. Gorelick | J. Baker | A. Lisco | I. Sereti | Harry A Mystakelis | M. Manion | E. Wilson | S. Krishnan | April Poole | Jorden L. Welker | Adam W. Rupert | Elizabeth Laidlaw
[1] P. Douglas,et al. Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators. , 2020, The Journal of infectious diseases.
[2] J. Mandrola,et al. Aspirin for Primary Atherosclerotic Cardiovascular Disease Prevention as Baseline Risk Increases: A Meta-Regression Analysis. , 2020, The American journal of medicine.
[3] K. Brummel-Ziedins,et al. Factor Xa Inhibition Reduces Coagulation Activity but Not Inflammation Among People With HIV: A Randomized Clinical Trial , 2020, Open forum infectious diseases.
[4] Michael T. Lu,et al. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. , 2019, American heart journal.
[5] Michael T. Lu,et al. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). , 2019, American heart journal.
[6] R. Gorelick,et al. A Phase I, Randomized, Controlled Clinical Study of CC-11050 in People Living With HIV With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE). , 2019, Open forum infectious diseases.
[7] K. H. Hullsiek,et al. The Effects of Recombinant Human Lactoferrin on Immune Activation and the Intestinal Microbiome Among Persons Living with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy. , 2019, The Journal of infectious diseases.
[8] Richard D Moore,et al. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. , 2019, The lancet. HIV.
[9] S. Kent,et al. Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial. , 2018, The lancet. HIV.
[10] M. Lederman,et al. Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone , 2018, The Journal of infectious diseases.
[11] A. Sher,et al. Inflammatory monocytes expressing tissue factor drive SIV and HIV coagulopathy , 2017, Science Translational Medicine.
[12] H. Hatano,et al. A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals , 2017, Pathogens & immunity.
[13] D. Moisi,et al. A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy , 2017, Open forum infectious diseases.
[14] H. Lane,et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.
[15] Jeffrey N. Martin,et al. UC Office of the President Recent Work Title The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD 4 + T cell recovery : a randomized crossover trial , 2014 .
[16] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Journal of the American College of Cardiology.
[17] R. Lempicki,et al. Evidence for innate immune system activation in HIV type 1-infected elite controllers. , 2014, The Journal of infectious diseases.
[18] N. Wong. Faculty Opinions recommendation of 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014 .
[19] M. Lederman,et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] J. Ananworanich,et al. Serious Non-AIDS events: Immunopathogenesis and interventional strategies , 2013, AIDS Research and Therapy.
[21] J. Berger,et al. Aspirin Attenuates Platelet Activation and Immune Activation in HIV-1-Infected Subjects on Antiretroviral Therapy: A Pilot Study , 2013, Journal of acquired immune deficiency syndromes.
[22] F. Pereyra,et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers , 2012, AIDS.
[23] S. Deeks,et al. Immunologic basis of cardiovascular disease in HIV-infected adults. , 2012, The Journal of infectious diseases.
[24] J. Skinner,et al. Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV , 2011, AIDS.
[25] Handan Wand,et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. , 2011, The Journal of infectious diseases.
[26] D. Follmann,et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. , 2011, The Journal of infectious diseases.
[27] S. Emery,et al. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. , 2010, The Journal of antimicrobial chemotherapy.
[28] V. Natarajan,et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection , 2010, AIDS.
[29] D. Jacobs,et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. , 2010, The Journal of infectious diseases.
[30] A. Phillips,et al. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity , 2009, BMJ : British Medical Journal.
[31] L. Calza,et al. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. , 2008, Current HIV research.
[32] Lewis H Kuller,et al. Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.
[33] A. Phillips,et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. , 2008, The Journal of infectious diseases.
[34] Susan Smyth,et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. , 2007, JAMA.
[35] J. Brenchley,et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Retrovirology.
[36] C. Rouzioux,et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] M. Lederman,et al. Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275). , 2017, Journal of clinical lipidology.